On March 1, 2024, the Food and Drug Administration (FDA) issued a letter of enforcement discretion stating that it does not intend to object to the use of qualified health claims relating to the yogurt consumption and the reduction of type 2 diabetes risk.
On 1 August 2023, the EU Commission published implementing Regulation (EU) 2023/1581 amending Implementing Regulation (EU) 2017/2470 as regards the conditions of use of the novel food ‘astaxanthin-rich oleoresin from Haematococcus pluvialis algae’. The new Regulation extends the conditions of use in food supplements for children aged 3 to less than 10 years and for adolescents aged 10 to less than 14 years of age (1).
Français